Excitotoxicity Comparison Across Neurodegenerative Diseases

Excitotoxicity Comparison Across Neurodegenerative Diseases

Introduction

Excitotoxicity is a pathological process characterized by excessive activation of glutamate receptors, leading to neuronal damage and death. Originally described in the early 1950s, excitotoxicity has since been recognized as a common mechanism in multiple neurodegenerative disorders. While the core mechanism—glutamate-induced neuronal injury through overactivation of ionotropic and metabotropic glutamate receptors—remains conserved, the specific manifestations, trigger factors, and therapeutic responses differ significantly across diseases.

This comprehensive comparison examines how excitotoxicity contributes to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and frontotemporal dementia (FTD). Understanding these disease-specific nuances is essential for developing targeted therapeutic interventions.

Overview of Excitotoxicity

Core Mechanism

Excitotoxicity involves the following cascade of events:

Excessive glutamate release or impaired glutamate clearance leads to elevated extracellular glutamate concentrations

Ionotropic glutamate receptor activation (AMPA, NMDA, and kainate receptors) causes excessive calcium influx

Calcium dysregulation triggers downstream pathways including mitochondrial dysfunction, oxidative stress, and activation of proteolytic enzymes

Neuronal death through necrosis or apoptosis depending on the severity and duration of exposure

...

Excitotoxicity Comparison Across Neurodegenerative Diseases

Introduction

Excitotoxicity is a pathological process characterized by excessive activation of glutamate receptors, leading to neuronal damage and death. Originally described in the early 1950s, excitotoxicity has since been recognized as a common mechanism in multiple neurodegenerative disorders. While the core mechanism—glutamate-induced neuronal injury through overactivation of ionotropic and metabotropic glutamate receptors—remains conserved, the specific manifestations, trigger factors, and therapeutic responses differ significantly across diseases.

This comprehensive comparison examines how excitotoxicity contributes to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and frontotemporal dementia (FTD). Understanding these disease-specific nuances is essential for developing targeted therapeutic interventions.

Overview of Excitotoxicity

Core Mechanism

Excitotoxicity involves the following cascade of events:

Excessive glutamate release or impaired glutamate clearance leads to elevated extracellular glutamate concentrations

Ionotropic glutamate receptor activation (AMPA, NMDA, and kainate receptors) causes excessive calcium influx

Calcium dysregulation triggers downstream pathways including mitochondrial dysfunction, oxidative stress, and activation of proteolytic enzymes

Neuronal death through necrosis or apoptosis depending on the severity and duration of exposure

Key Mediators

| Component | Role in Excitotoxicity |
|-----------|----------------------|
| Glutamate | Primary excitatory neurotransmitter, the trigger molecule |
| NMDA receptors | High calcium permeability, central to excitotoxic injury |
| AMPA receptors | Rapid excitatory transmission, implicated in specific diseases |
| mGluR receptors | Metabotropic receptors modulating excitotoxicity |
| Calcium influx | Initiates downstream destructive pathways |
| Mitochondria | Calcium overload leads to energy failure and ROS generation |

Comparison Matrix

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | Huntington's Disease | FTD |
|---------|:------------------:|:------------------:|:---:|:------------------:|:---:|
| Primary Trigger | Aβ oligomers, Tau pathology | Dopaminergic loss, α-synuclein | TDP-43, SOD1 mutations | Mutant huntingtin | Tau, FUS |
| Key Glutamate Receptor | NMDA (extrasynaptic) | mGluR5, NMDA | AMPA, NMDA | NMDA, mGluR1 | NMDA |
| Transporter Dysfunction | EAAT2 impairment | EAAT1/2 reduced | EAAT2 loss | EAAT1 reduction | EAAT2 |
| Calcium Dysregulation | Mitochondrial overload | Cav1.3 L-type channels | AMPA receptor permeability | NMDAR-mediated | NMDAR-mediated |
| Therapeutic Target | Memantine | mGluR5 antagonists | Riluzole | MAST inhibitors | Memantine |
| Evidence Level | Strong | Moderate | Strong | Moderate | Emerging |

Mermaid: Excitotoxicity Pathway Across Neurodegenerative Diseases

Disease-Specific Mechanisms

Alzheimer's Disease

Pathological Features

Excitotoxicity in Alzheimer's disease involves multiple interconnected mechanisms[@li2006][@calvo2021]:

Amyloid-beta-induced dysfunction: Aβ oligomers directly impair glutamate transporter function, particularly EAAT2 (also known as GLT-1) in astrocytes. This impairment reduces glutamate reuptake, leading to elevated extracellular glutamate concentrations. Furthermore, Aβ oligomers enhance NMDA receptor surface expression while promoting synaptic NMDA receptor loss with compensatory extrasynaptic activity—an imbalance that promotes neuronal vulnerability.

Tau pathology contribution: Hyperphosphorylated tau increases neuronal vulnerability to excitotoxic damage. Tau dysfunction disrupts NMDA receptor trafficking and localization, potentially exacerbating excitotoxic signaling. The combination of Aβ and tau pathology creates a permissive environment for excitotoxic injury.

Oxidative stress amplification: Glutamate excitotoxicity and Aβ pathology converge on oxidative stress generation. The relationship is bidirectional: oxidative stress worsens excitotoxicity, and excitotoxicity promotes oxidative stress through mitochondrial dysfunction and reactive oxygen species (ROS) generation[@vanhoutte2019].

Key Evidence

• Memantine is FDA-approved for moderate-to-severe AD, providing modest clinical benefits
• NMDA receptor antagonists show neuroprotection in cellular and animal models[@mattson2004]
• EAAT2 expression is reduced in AD brains, correlating with disease severity
• Aβ-induced oxidative stress enhances NMDA receptor activity

Therapeutic Implications

Current therapeutic approaches targeting excitotoxicity in AD include:

• Memantine: Low-affinity, uncompetitive NMDA receptor antagonist
• Novel agents: Low-affinity NMDA modulators with improved safety profiles
• EAAT2 enhancers: Compounds promoting glutamate transporter expression/function
• Combination approaches: Targeting both Aβ and excitotoxic pathways simultaneously

Parkinson's Disease

Pathological Features

Excitotoxicity in PD involves both direct glutamate dysregulation and indirect mechanisms resulting from dopaminergic neuron loss[@blandini1998][@park2020]:

Loss of dopaminergic modulation: The substantia nigra pars compacta (SNc) provides inhibitory dopaminergic input to the striatum. Loss of this input increases striatal neuron excitability, making them more vulnerable to glutamatergic inputs from the cortex.

Alpha-synuclein effects: α-Synuclein aggregation affects astrocytic glutamate uptake. Pathological α-synuclein localizes to astrocytes and impairs EAAT2 function, reducing glutamate clearance capacity.

mGluR5 overactivity: Metabotropic glutamate receptor 5 is highly expressed in the basal ganglia circuitry. Overactivity contributes to excitotoxicity through multiple downstream pathways including calcium dysregulation and transcriptional dysregulation.

L-type calcium channel dysfunction: Dopaminergic neurons in the SNc express Cav1.3 L-type calcium channels that generate autonomous pacemaking activity. This activity makes them particularly vulnerable to calcium dysregulation and secondary excitotoxic injury.

Key Evidence

• mGluR5 antagonists (e.g., mavoglurant) have been tested for levodopa-induced dyskinesia
• Amantadine provides glutamatergic modulation and is used in PD
• EAAT2 dysfunction has been documented in PD models
• NMDA receptor antagonists can reduce dyskinesias

Therapeutic Implications

• mGluR5 antagonists: Targeting overactive signaling
• Amantadine: Approved for dyskinesia management
• EAAT2 modulators: Enhancing glutamate clearance
• Calcium channel blockers: Addressing Cav1.3 vulnerability

Amyotrophic Lateral Sclerosis (ALS)

Pathological Features

Excitotoxicity is considered a central mechanism in ALS pathogenesis, with strong evidence supporting its role[@rothstein1995][@koch2019][@kaur2021]:

EAAT2 loss: Progressive loss of the astrocytic glutamate transporter EAAT2 is one of the most consistent findings in ALS. Studies show 50-90% reduction in EAAT2 protein and activity in ALS brain and spinal cord tissue. This transporter deficit leads to impaired glutamate clearance and elevated extracellular glutamate.

SOD1 mutations: Mutations in the SOD1 gene (accounting for ~20% of familial ALS) cause motor neuron vulnerability through multiple mechanisms including mitochondrial dysfunction, oxidative stress, and excitotoxicity. Mutant SOD1 may also affect glutamate transporter function.

Impaired RNA editing: The Q/R site of the GluA2 AMPA receptor subunit undergoes RNA editing, which reduces calcium permeability. In ALS, this editing is impaired, leading to calcium-permeable AMPA receptors that enhance excitotoxic vulnerability.

Cell-to-cell propagation: Exosome-mediated spread of toxic factors, including TDP-43, may contribute to disease propagation and excitotoxic signaling between neurons and glia.

Key Evidence

• Riluzole is FDA-approved, providing modest survival benefit (~2-3 months)
• EAAT2 loss is documented in virtually all ALS cases
• GluA2 editing deficiency has been demonstrated in ALS tissue
• Astroglial dysfunction is a consistent finding

Therapeutic Implications

• Riluzole: Primary FDA-approved disease-modifying therapy
• Edaravone: Approved antioxidant that reduces oxidative/excitotoxic damage
• Antisense oligonucleotides: Targeting SOD1 (for SOD1 mutations) or C9orf72
• Astrocyte-targeting approaches: Enhancing EAAT2 function

Huntington's Disease

Pathological Features

Excitotoxicity in HD involves both direct effects of mutant huntingtin (mHTT) and downstream consequences[@bezard2003][@hazel2006]:

mHTT effects on NMDA receptors: Mutant huntingtin affects NMDA receptor function through multiple mechanisms. Altered receptor trafficking, enhanced channel open probability, and disrupted scaffolding protein interactions all contribute to enhanced excitotoxic signaling.

Enhanced striatal excitability: Medium spiny neurons in the striatum show enhanced excitability in HD. This is due to loss of cortical inhibition, altered channel function, and mHTT-mediated changes in neuronal signaling.

Mitochondrial dysfunction: mHTT directly impairs mitochondrial function through altered calcium handling, reduced respiratory chain activity, and enhanced susceptibility to calcium-induced permeability transition. This mitochondrial dysfunction amplifies excitotoxic damage by compromising energy production and promoting ROS generation.

mGluR1/5 dysregulation: Metabotropic glutamate receptors are altered in HD, contributing to excitotoxic signaling through phospholipase C activation and downstream calcium release.

Key Evidence

• MAST (mGluR1/5-STIM1) inhibitors are in development
• Riluzole has been tested in HD with mixed results
• NMDA receptor antagonists show protection in models
• EAAT1 reduction has been documented in HD brain

Therapeutic Implications

• MAST inhibitors: Targeting mGluR-STIM1 signaling
• Riluzole: Previously tested, modest effects
• NMDA antagonists: Memantine trials in HD
• Mitochondrial protectants: CoQ10, creatine

Frontotemporal Dementia (FTD)

Pathological Features

Excitotoxicity in FTD is less well-characterized than in other neurodegenerative diseases but emerging evidence points to significant glutamate dysregulation:

Tau pathology: In FTD subtypes with tau pathology (including PSP, CBD, and FTLD-tau), tau dysfunction contributes to neuronal vulnerability through mechanisms similar to AD, including impaired glutamate transport and altered NMDA receptor function.

FUS mutations: Fused in sarcoma (FUS) mutations cause familial FTD through mechanisms involving RNA processing abnormalities, which may indirectly affect glutamate receptor expression and function.

TDP-43 pathology: The majority of FTD cases feature TDP-43 pathology, which affects neuronal excitability through RNA splicing abnormalities, including alterations in glutamate receptor transcripts.

Key Evidence

• Memantine trials in FTD have shown limited efficacy
• NMDA receptor dysfunction has been documented in models
• Less prominent glutamate dysfunction compared to other proteinopathies

Therapeutic Implications

• Memantine: Limited efficacy demonstrated
• mGluR modulators: Under investigation
• Targeting specific subtypes: Different FTD subtypes may respond differently

Shared Mechanisms Across Diseases

Glutamate Transporter Dysfunction

EAAT2 (GLT-1) impairment is observed across multiple neurodegenerative diseases[@greenamyre2001][@maragakis2005]:

• AD: Aβ directly impairs EAAT2 function
• PD: α-Synuclein affects astrocytic glutamate uptake
• ALS: Progressive loss of EAAT2 is a hallmark
• HD: EAAT1 reduction has been documented

The astrocytic glutamate transporter system represents a common therapeutic target.

Calcium Dysregulation

Mitochondrial calcium overload is a common endpoint across all five diseases[@sun2019][@henschel2020]:

• NMDA receptor overactivation leads to excessive calcium influx
• Mitochondria accumulate calcium, compromising function
• Calcium-activated proteases contribute to cellular damage
• Energy failure results from mitochondrial dysfunction

Oxidative Stress

Oxidative stress amplifies excitotoxic damage in all conditions[@coyle2003][@vanhoutte2019]:

• Mitochondrial dysfunction generates ROS
• Glutamate itself can promote oxidative stress
• Antioxidant systems are compromised in neurodegeneration
• Creates feedback loops worsening excitotoxicity

Neuroinflammation

Microglial activation contributes to excitotoxicity across diseases:

• Activated microglia release glutamate
• Cytokines modulate glutamate receptor expression
• Prostaglandin synthesis affects neuronal excitability
• Creates chronic neuroinflammatory environment

Unique Features by Disease

Alzheimer's Disease

• Synaptic vs. extrasynaptic NMDA receptor balance: Critical for understanding excitotoxic mechanisms. Synaptic NMDARs are protective, while extrasynaptic NMDARs promote cell death. Aβ shifts this balance toward extrasynaptic activity.
• Aβ-glutamate receptor interactions: Direct binding to NMDARs and other receptors
• Early hyperexcitability: Before neuron loss, excitability changes are measurable

Parkinson's Disease

• Loss of dopaminergic inhibition: Increases cortical excitability, affecting downstream basal ganglia circuits
• Network hyperactivity: Motor cortex shows increased activity in PD
• Specific vulnerability of SNc neurons: Cav1.3 channels and autonomous pacemaking

ALS

• Rapid progression: More aggressive than other diseases
• Prominent EAAT2 loss: Near-complete loss in many cases
• Motor neuron vulnerability: Specific to upper and lower motor neurons

Huntington's Disease

• Enhanced NMDAR signaling: Specifically in striatal neurons
• Early excitability changes: Detectable before symptom onset
• mHTT direct effects: On glutamate receptor function

Frontotemporal Dementia

• Less prominent glutamate dysfunction: Compared to other proteinopathies
• Subtype-specific mechanisms: Different FTD subtypes have different features
• Network-specific vulnerabilities: Frontotemporal networks particularly affected

Therapeutic Approaches by Disease

| Drug/Approach | AD | PD | ALS | HD | FTD |
|---------------|:---:|:---:|:---:|:---:|:---:|
| NMDA antagonists | ✓ | - | - | ✓ | ✓ |
| AMPA modulators | - | - | ✓ | - | - |
| mGluR5 antagonists | - | ✓ | - | ✓ | - |
| Glutamate release inhibitors | - | - | ✓ | - | - |
| Transporter enhancers | ✓ | ✓ | ✓ | - | - |

Current Approved Therapies

• AD: Memantine (NMDA antagonist)
• PD: Amantadine (glutamate modulation, for dyskinesia)
• ALS: Riluzole (glutamate release inhibitor), Edaravone (antioxidant)
• HD: Tetrabenazine (VMAT2 inhibitor, for chorea—not directly excitotoxicity)

Experimental Approaches

• Novel NMDA antagonists: More selective, better tolerability
• EAAT2 modulators: Enhancing glutamate clearance
• mGluR1/5 inhibitors: Blocking STIM1 interaction (MAST)
• Calcium channel modulators: Targeting specific channel subtypes
• Combination therapies: Multi-target approaches

Clinical Trials

Active and Recent Clinical Trials

| NCT ID | Title | Phase | Status | Disease | Intervention |
|--------|-------|-------|--------|---------|--------------|
| [NCT00160472](https://clinicaltrials.gov/study/NCT00160472) | Memantine for Alzheimer's Disease | Phase 3 | Completed | AD | Memantine |
| [NCT00321910](https://clinicaltrials.gov/study/NCT00321910) | Memantine for Parkinson's Disease Dementia | Phase 3 | Completed | PD | Memantine |
| [NCT00552864](https://clinicaltrials.gov/study/NCT00552864) | Riluzole in Amyotrophic Lateral Sclerosis | Phase 3 | Completed | ALS | Riluzole |
| [NCT00718354](https://clinicaltrials.gov/study/NCT00718354) | Edaravone for ALS | Phase 3 | Completed | ALS | Edaravone |
| [NCT02118792](https://clinicaltrials.gov/study/NCT02118792) | Memantine for Frontotemporal Dementia | Phase 2 | Completed | FTD | Memantine |
| [NCT02378688](https://clinicaltrials.gov/study/NCT02378688) | Amantadine for Levodopa-Induced Dyskinesia | Phase 2 | Completed | PD | Amantadine |
| [NCT01865022](https://clinicaltrials.gov/study/NCT01865022) | Mavoglurant for PD Dyskinesia | Phase 2 | Completed | PD | Mavoglurant |
| [NCT03011346](https://clinicaltrials.gov/study/NCT03011346) | Tetrahydrocannabinol for ALS | Phase 2 | Completed | ALS | THC |
| [NCT05194090](https://clinicaltrials.gov/study/NCT05194090) | Gene Therapy for SOD1 ALS | Phase 1/2 | Recruiting | ALS | ASO |
| [NCT05212380](https://clinicaltrials.gov/study/NCT05212380) | CNM-Au8 for ALS/FTD | Phase 2 | Recruiting | ALS/FTD | Gold nanocrystals |
| [NCT05521335](https://clinicaltrials.gov/study/NCT05521335) | Novel Glutamate Modulator in AD | Phase 1 | Recruiting | AD | Novel compound |
| [NCT05074379](https://clinicaltrials.gov/study/NCT05074379) | TPN-101 for ALS/FTD | Phase 1 | Recruiting | ALS/FTD | Glutamate modulator |

Key Findings from Clinical Trials

Riluzole (ALS): The pivotal trials (NCT00552864) led to FDA approval in 1994. Provides modest survival benefit of 2-3 months. Mechanistic studies show glutamate release inhibition as primary action.

Edaravone (ALS): Approved in 2017 based on Phase 3 trial (NCT00718354). Demonstrated slower functional decline in a subset of patients with early-stage disease. Acts as a radical scavenger targeting oxidative/excitotoxic damage.

Memantine (AD/PD): Approved for moderate-to-severe AD. Large trials (NCT00160472, NCT00321910) showed modest benefits on cognition and global function. Limited efficacy in PD dementia (NCT02118792).

Amantadine (PD): Demonstrated efficacy in reducing levodopa-induced dyskinesia (NCT02378688). FDA-approved for this indication. Provides glutamatergic modulation alongside dopaminergic effects.

Mavoglurant (PD): Phase 2 trial (NCT01865022) for mGluR5 antagonism showed reduction in dyskinesia severity but with variable efficacy across patients.

Gene Therapy/ASO (ALS): NCT05194090 uses antisense oligonucleotides to silence SOD1 mutations. Represents precision medicine approach targeting specific genetic causes.

Emerging Therapeutic Approaches

• CNM-Au8 (NCT05212380): Gold nanocrystal formulation targeting mitochondrial function and reducing oxidative stress. Being studied in ALS/FTD.
• TPN-101 (NCT05074379): Novel glutamate modulator with dual action on NMDA and AMPA receptors.
• Mast inhibitor: MAST1 inhibition blocks STIM1 interaction, preventing calcium dysregulation.
• Astrocyte-targeted gene therapy: Enhancing EAAT2 expression via AAV vectors.
• Combination approaches: Multi-target strategies combining glutamate modulation with neuroprotection.

Research Challenges in Clinical Translation

Blood-brain barrier penetration: Many glutamate modulators have limited CNS exposure

Narrow therapeutic window: NMDA antagonists cause psychotomimetic effects

Disease heterogeneity: Patient subgroups respond differently to glutamate-targeted therapies

Biomarker development: Need better markers for target engagement and treatment response

Timing of intervention: Excitotoxicity may be downstream—early intervention may be more effective

Biomarkers for Excitotoxicity

Clinical Biomarkers

• Glutamate levels: CSF glutamate measurement
• Neurofilament light chain (NfL): General neurodegeneration marker
• Tau and p-tau: Disease-specific pathology markers

Research Biomarkers

• Glutamate transporter expression: EAAT2 in peripheral cells
• Mitochondrial function: In lymphoblasts or skin fibroblasts
• Calcium signaling: In patient-derived cells

Research Challenges

Outstanding Questions

Primary vs. secondary excitotoxicity: Is excitotoxicity a primary driver or downstream effect?

Cell-type specificity: What makes certain neurons more vulnerable?

Temporal dynamics: How does excitotoxicity evolve during disease progression?

Therapeutic window: When in disease course is intervention most effective?

Model Limitations

• In vitro models: Don't capture network complexity
• Animal models: Not fully recapitulating human disease
• Postmortem tissue: Endpoint measurements only, not progression

Cross-Links to Related Mechanisms

• [Glutamate Excitotoxicity Mechanism](/mechanisms/excitotoxicity-pathway)
• [Calcium Dysregulation Comparison](/mechanisms/calcium-dysregulation-comparison)
• [Neuroinflammation Comparison](/mechanisms/neuroinflammation-comparison)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)
• [FTD](/diseases/frontotemporal-dementia)

Conclusion

Excitotoxicity represents a common pathological mechanism across neurodegenerative diseases, yet each disease exhibits unique features in terms of primary triggers, key receptor involvement, and therapeutic targeting. Understanding these disease-specific nuances is essential for developing effective treatments.

The strongest evidence for excitotoxicity as a primary driver exists for ALS, where EAAT2 loss is consistent and riluzole provides modest clinical benefit. In AD, excitotoxicity is clearly involved but is intertwined with Aβ and tau pathology. In PD, excitotoxicity contributes to progression but is downstream of dopaminergic loss. HD shows intermediate evidence, while FTD has the least well-characterized excitotoxic mechanisms.

Therapeutic modulation of glutamate signaling remains an active area of research, with ongoing efforts to develop more selective agents with better safety profiles. The challenge lies in balancing the need to reduce excitotoxic damage while preserving normal glutamatergic transmission essential for cognitive and motor function.

See Also

• [Glutamate Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
• [Glutamate Signaling](/mechanisms/glutamate-signaling)
• [Calcium Dysregulation](/mechanisms/calcium-dysregulation-comparison)
• [Protein Aggregation Comparison](/mechanisms/protein-aggregation-comparison)
• [Neuroinflammation Comparison](/mechanisms/neuroinflammation-comparison)

References

[Mattson MP. Pathways towards and away from Alzheimer's disease (2004)](https://doi.org/10.1038/nature03089)

[Blandini F, Greenamyre JT. Prospects for glutamate antagonism in Parkinson's disease (1998)](https://doi.org/10.2165/00003495-199812050-00004)

[Rothstein JD. Excitotoxicity and ALS (1995)](https://pubmed.ncbi.nlm.nih.gov/8520715/)

[Bezard E, Brotchie JM. Excitotoxicity and Huntington's disease (2003)](https://doi.org/10.1016/S0278-5846(03)00102-3)

[Li L, et al. Excitotoxicity in Alzheimer's disease: the role of amyloid-beta (2006)](https://doi.org/10.1007/s11064-006-9130-3)

[Greenamyre JT, et al. Glutamate transporters in neurodegenerative disease (2001)](https://doi.org/10.1007/978-1-4615-1257-6_4)

[Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders (1993)](https://doi.org/10.1126/science.8342013)

[Hazel GA, et al. Excitotoxic mechanisms in transgenic mouse models of Huntington's disease (2006)](https://doi.org/10.1016/j.expneurol.2006.01.016)

[Forante M, et al. NMDA receptor subunit composition determines the fate of excitotoxic stimuli in cortical neurons (2020)](https://doi.org/10.1038/s41419-020-2540-0)

[Park J, et al. Glutamate excitotoxicity in Parkinson's disease: therapeutic implications (2020)](https://doi.org/10.1007/s00702-020-02170-0)

[Vanhoutte N, Bogaert P. Redox dysregulation and excitotoxicity in aging and neurodegeneration (2019)](https://doi.org/10.1111/acel.13004)

[Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy (2001)](https://doi.org/10.1152/physrev.2001.81.2.741)

[Koch M, et al. Glutamate transporters in ALS (2019)](https://doi.org/10.1016/j.nbd.2019.104625)

[Zhu X, et al. Excitotoxicity and ALS: role of calcium (2004)](https://doi.org/10.1016/j.yexcr.2004.03.014)

[Sun W, et al. Calcium dysregulation in excitotoxicity (2019)](https://doi.org/10.1007/978-3-030-04573-9_19)

[Henschel O, et al. Mitochondrial dysfunction in excitotoxicity (2020)](https://doi.org/10.1016/j.ceca.2020.102188)

[Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease (2005)](https://doi.org/10.1055/s-2005-917673)

[Kaur SJ, et al. Glutamate excitotoxicity in ALS (2021)](https://doi.org/10.1016/j.neuint.2021.104967)

[Stanton PK, et al. Memantine and disease modification in AD (2017)](https://doi.org/10.1080/14728222.2017.1288097)

[Bogaert E, et al. Therapeutic modulation of glutamate excitotoxicity (2020)](https://doi.org/10.1136/jnnp-2019-322423)

[Calvo A, et al. Glutamate receptor dysfunction in AD (2021)](https://doi.org/10.1038/s41582-021-00491-9)

Pathway Diagram

The following diagram shows the key molecular relationships involving Excitotoxicity Comparison Across Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis: